Anemia management and chronic renal failure progression

Kidney International

Volumn 68, Issue SUPPL. 99, 2005, Pages

  Rossert, Jerome ^a,b   Froissart, Marc ^a   Jacquot, Christian ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Anemia; Chronic kidney disease; Erythropoietin; Progression

Indexed keywords

ERYTHROPOIETIN; FAS LIGAND; HEMOGLOBIN; PROTEIN BCL XL; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; X LINKED INHIBITOR OF APOPTOSIS; ANTIANEMIC AGENT; ERYTHROPOIETIN RECEPTOR;

ANEMIA; APOPTOSIS; CARDIOVASCULAR DISEASE; CELL DESTRUCTION; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DISEASE COURSE; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; ERYTHROCYTE CONCENTRATE; FIBROSING ALVEOLITIS; HUMAN; HYPOXIA; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; POST HOC ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SIGNAL TRANSDUCTION; BLOOD; CLINICAL TRIAL; DIABETIC NEPHROPATHY; ERYTHROCYTE COUNT; NEPHRON; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; PROTEIN BINDING; RETROSPECTIVE STUDY; REVIEW;

ANEMIA; APOPTOSIS; CLINICAL TRIALS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EPOETIN ALFA; ERYTHROCYTE COUNT; ERYTHROPOIETIN; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHRONS; PROSPECTIVE STUDIES; PROTEIN BINDING; RECEPTORS, ERYTHROPOIETIN; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33748317810     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09914.x     Document Type: Conference Paper

References (42)

1. Meguid El, NAHAS A, BELLO AK: Chronic kidney disease: The global challenge. Lancet 365:331-340, 2005
2. GRUNE T, SOMMERBURG O, SIEMS WG: Oxidative stress in anemia. Clin Nephrol 53:S18-22, 2000
3. ROSSERT J, ECKARDT KU: Erythropoietin receptors: Their role beyond erythropoiesis. Nephrol Dial Transplant 20:1025-1028, 2005
4. YANG CW, LI C, JUNG JY, SHIN SJ, et al: Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 17:1754-1755, 2003
5. PATEL NS, SHARPLES EJ, CUZZOCREA S, et al: Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 66:983-989, 2004
6. SHARPLES EJ, PATEL N, BROWN P, et al: Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15:2115-2124, 2004
7. GONG H, WANG W, KWON TH, et al: EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int 66:683-695, 2004
8. VESEY DA, CHEUNG C, PAT B, et al: Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 19:348-355, 2004
9. WU H, LEE SH, GAO J, et al: Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 126:3597-3605, 1999
10. YU X, SHACKA JJ, EELLS JB, et al: Erythropoietin receptor signalling is required for normal brain development. Development 129:505-516, 2002
11. KERTESZ N, WU J, CHEN TH, et al: The role of erythropoietin in regulating angiogenesis. Dev Biol 276:101-110, 2004
12. RIBATTI D, PRESTA M, VACCA A, et al: Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627-2636, 1999
13. CARLINI RG, REYES AA, ROTHSTEIN M: Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 47:740-745, 1995
14. BAHLMANN FH, SONG R, BOEHM SM, et al: Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 110:1006-1012, 2004
15. DIGICAYLIOGLU M, LIPTON SA: Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412:641-647, 2001
16. NEURINGER JR, BRENNER BM: Hemodynamic theory of progressive renal disease: A 10-year update in brief review. Am J Kidney Dis 22:98-104, 1993
17. REMUZZI A, MAZERSKA M, GEPHARDT GN, et al: Three-dimensional analysis of glomerular morphology in patients with subtotal nephrectomy. Kidney Int 48:155-162, 1995
18. BOHLE A, CHRIST H, GRUND KE, MACKENSEN S: The role of the interstitium of the renal cortex in renal disease. Contrib Nephrol 16:109-114, 1979
19. D'AMICO G, FERRARIO F, RASTALDI MP: Tubulointerstitial damage in glomerular diseases: Its role in the progression of renal damage. Am J Kidney Dis 26:124-132, 1995
20. WEHRMANN M, BOHLE A, BOGENSCHUTZ O, et al: Long-term prognosis of chronic idiopathic membranous glomerulonephritis. An analysis of 334 cases with particular regard to tubulointerstitial changes. Clin Nephrol 31:67-76, 1989
21. WEHRMANN M, BOHLE A, HELD H, et al: Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 33:115-122, 1990
22. BOGENSCHUTZ O, BOHLE A, BATZ C, et al: IgA nephritis: On the importance of morphological and clinical parameters in the longterm prognosis of 239 patients. Am J Nephrol 10:137-147, 1990
23. BOHLE A, MULLER GA, WEHRMANN M, et al: Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int Suppl 54:S2-9, 1996
24. FINE LG, ORPHANIDES C, NORMAN JT: Progressive renal disease: The chronic hypoxia hypothesis. Kidney Int Suppl 65:S74-78, 1998
25. NAKAGAWA T, KANG DH, OHASHI R, et al: Tubulointerstitial disease: Role of ischemia and microvascular disease. Curr Opin Nephrol Hypertens 12:233-241, 2003
26. KANG DH, KANELLIS J, HUGO C, et al: Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 13:806-816, 2002
27. NIR A, CLAVELL AL, HEUBLEIN D, et al: Acute hypoxia and endogenous renal endothelin. J Am Soc Nephrol 4:1920-1924, 1994
28. ORPHANIDES C, FINE LG, NORMAN JT: Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism. Kidney Int 52:637-647, 1997
29. NORMAN JT, CLARK IM, GARCIA PL: Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 58:2351-2366, 2000
30. MARCUSSEN N: Tubulointerstitial damage leads to atubular glomeruli: Significance and possible role in progression. Nephrol Dial Transplant 15 Suppl 6:74-75, 2000
31. GANDHI M, OLSON JL, MEYER TW: Contribution of tubular injury to loss of remnant kidney function. Kidney Int 54:1157-1165, 1998
32. NATH KA, GRANDE J, CROATT A, et al: Redox regulation of renal DNA synthesis, transforming growth factor-beta1 and collagen gene expression. Kidney Int 53:367-381, 1998
33. SUNG FL, ZHU TY, AU-YEUNG KK, et al: Enhanced MCP-1 expression during ischemia/reperfusion injury is mediated by oxidative stress and NF-kappaB. Kidney Int 62:1160-1170, 2002
34. GEESIN JC, HENDRICKS LJ, FALKENSTEIN PA, et al: Regulation of collagen synthesis by ascorbic acid: Characterization of the role of ascorbate-stimulated lipid peroxidation. Arch Biochem Biophys 290:127-132, 1991
35. HOUGLUM K, BRENNER DA, CHOJKIER M: d-alpha-tocopherol inhibits collagen alpha 1(I) gene expression in cultured human fibroblasts. Modulation of constitutive collagen gene expression by lipid peroxidation. J Clin Invest 87:2230-2235, 1991
36. ALLEN DA, HARWOOD S, VARAGUNAM M, et al: High glucose-induced oxidative stress causes apoptosis in proximal tubular epithelial cells and is mediated by multiple caspases. Faseb J 17:908-910, 2003
37. EDDY AA: Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. Kidney Int 50:1139-1149, 1996
38. ROTH D, SMITH RD, SCHULMAN G, et al: Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24:777-784, 1994
39. KURIYAMA S, TOMONARI H, YOSHIDA H, et al: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176-185, 1997
40. GOUVA C, NIKOLOPOULOS P, IOANNIDIS JP, SIAMOPOULOS KC: Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int 66:753-760, 2004
41. JUNGERS P, CHOUKROUN G, OUALIM Z, et al: Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16:307-312, 2001
42. KEANE WF, LYLE PA: Recent advances in management of type 2 diabetes and nephropathy: Lessons from the RENAAL study. Am J Kidney Dis 41:S22-25, 2003